Markers of bone metabolism in patients with type 2 diabetes mellitus

Authors

  • Beata Wojtysiak-Duma Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author
  • Arleta Malecha-Jędraszek Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author https://orcid.org/0000-0002-9104-9760
  • Agata Burska Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author
  • Helena Donica Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author https://orcid.org/0000-0003-0677-7825
  • Beata Matuszek Chair and Department of Endocrinology Author
  • Monika Lenart-Lipińska Department of Laboratory Diagnostics, Medical University of Lublin Author https://orcid.org/0000-0002-3418-6830
  • Andrzej Nowakowski Chair and Department of Endocrinology Author

DOI:

https://doi.org/10.12923/

Keywords:

bone markers, metabolism, bone, type 2 diabetes mellitus, CTx, PTH, ALP

Abstract

There are only a few reports on bone metabolism in type 2 diabetes. Impaired bone turnover in type 2 diabetes appears to result from decreased bone formation. Some studies suggest that poor glycaemic control in type 2 diabetes may contribute to osteopaenia. The aim of our study was to investigate biochemical markers of bone turnover in patients with type 2 diabetes. In our study 51 type 2 diabetes mellitus patients and 30 healthy persons were enrolled. 30 of the patients had macrovascular complications and 19 of them had microangiopathies. The mean age of the patients was 62.3 (9.3) years and the mean disease duration was 11.1 (7.0) years. Serum crosslaps (C-telopeptide, CTx), parathyroid hormone (PTH), calcium, inorganic phosphate, glucose, HbA1c, alkaline phosphatase and creatinine were measured. No differences between patients and controls were observed in serum PTH concentration and alkaline phosphatase activity. Patients had lower serum levels of CTX than controls [0.309 (0.277) vs 0.396 (0.196), p< 0.05]. In turn, serum levels of calcium and inorganic phosphates were higher in diabetic patients in comparison to the control group. We found a significant statistical correlation between CTx levels and PTH (r=0.48. p< 0.05). We also noticed a positive relationship between CTX, PTH and creatinine concentration. Our study suggests that decreased serum CTX levels in type 2 diabetes mellitus patients may be an effect of altered equilibrium in bone formation and resorption processes. A significant correlation between PTH and CTX and creatinine concentration indicate that renal function in diabetes patients may affect serum levels of bone metabolism markers.

References

1. Achemlal L., Tellal S., Rkiouak F. et al.: Bone metabolism in male patients with type 2 diabetes. Clin. Rheumatol., 24, 493, 2005.

2. Capoglu I., Ozkan A., Ozkan B. et al.: Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels. J. Int. Med. Res., 36, 1392, 2008.

3. Cutrim D.M., Pereira F.A., Paula F.J.A. et al.: Lack of relationship between glycemic control and bone mineral density in type 2 diabetes mellitus. Braz. J. Med. Biol. Res., 40, 221, 2007.

4. Dennison E.M., Syddall H.E., Aihie Sayer A. et al.: Type 2 diabetes mellitus is associated with increased axial bone density in men and woman from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resisrance? Diabetologia, 47, 1963, 2004.

5. Leidig-Bruckner G., Ziegler R.: Diabetes mellitus a risk for osteoporosis? Exp. Clin. Endocrinol. Diabetes, 09, S493, 2001.

6. Okazaki R., Totsuka Y., Hamano K. et al.: Metabolic improvefment of poorly controlled non insulin dependent diabetes mellitus decreases bone turnover. J. Clin. Endocrinol. Metab., 82, 2915, 1997.

7. Oz S.G., Guven G.S., Kilicarslan A. et al.: Evaluation bone metabolism and bone mass in patients with type 2 diabetes mellitus. J. Natl. Med. Assoc., 98, 1598, 2006.

8. Rosato M.T., Schneider S.H., Shapses S.A.: Bone turnover and insulin-like growth factor-1 levels increase after improved glycemic control in non insulin-dependent diabetes mellitus. Calcif. Tissue Int., 63, 107, 1998.

9. Suzuki K., Kurose T., Takizawa M. et al.: Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus. Diab. Res. Clin. Pract., 68, 117, 2005.

10. Thrailkill K.M., Lumpkin C.K., Bunn R.C. et al.: Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am. J. Physiol. Endocrinol. Metab., 289, E735, 2005.

11. Vestergaard P.: Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr. Opin. Endocrinol. Diabetes Obes., 16, 125, 2009.

12. Yendt E.R., Cohanim M., Jarzylo S. et al.: Reduced creatinine clearance in primary osteoporosis in women. J. Bone Miner. Res., 8, 1045, 1993.

Downloads

Published

2025-04-09

Issue

Vol. 23 No. 2 (2010): Annales UMCS, Pharmacia, Sectio DDD, Volume XXIII

Section

Artykuły

License

Copyright (c) 2010 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.